


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (currently amended): A method for inducing cell death in a myeloma cancer cell, comprising contacting said myeloma cancer cell with an isocoumarin derivative of the formula:



and further contacting said myeloma cancer cell with a glucocorticoid, wherein the dose of said isocoumarin derivative when combined with the dose of said glucocorticoid is effective to induce cell death in said myeloma cancer cell.

2 (currently amended): The method of claim 2, wherein said inducing cell death comprises inducing apoptosis.


3 (canceled).

4 (previously presented): The method of claim 4, wherein said glucocorticoid is dexamethasone or prednisone.

5 (Currently amended): The method of claim 1, further comprising contacting said myeloma cancer cell with one or more other chemotherapeutic agents.

6 (previously presented): The method of claim 5, wherein said one or more other chemotherapeutic agents is or are selected from the group consisting of vincristine, doxorubicin, cyclophosphamide, etoposide, cisplatin, melphalan, mitoxantrone, BCNU, idarubicin, procarbazine, and cytoxan.

7 (currently amended): A method for inhibiting the proliferation of a myeloma cancer cell, comprising contacting said myeloma cancer with an isocoumarin derivative of the formula:



and further contacting said myeloma cancer cell with a glucocorticoid, wherein the dose of said isocoumarin derivative when combined with the dose of said glucocorticoid is effective to inhibit the proliferation of said myeloma cancer cell.


8 (cancelled).

9 (previously presented): The method of claim 8, wherein said glucocorticoid is dexamethasone or prednisone.

10 (currently amended): The method of claim 7, further comprising contacting said myeloma cancer cell with one or more other chemotherapeutic agents.

11 (previously presented): The method of claim 10, wherein said one or more other chemotherapeutic agents is or are selected from the group consisting of vincristine, doxorubicin, cyclophosphamide, etoposide, cisplatin, melphalan, mitoxantrone, BCNU, idarubicin, procarbazine, and cytoxan.


12 (previously presented): A method for treating multiple myeloma in a human patient, comprising administering an isocoumarin derivative of the formula:



and administering a glucocorticoid as a second treatment modality, wherein the administration of said isocoumarin derivative when combined with the administration of said glucocorticoid, is effective to treat said multiple myeloma.

13 (previously presented): The method of claim 12, wherein said glucocorticoid is dexamethasone or prednisone.

14 (previously presented): A method for treating multiple myeloma in a human patient, comprising administering an isocoumarin derivative of the formula:



and administering a glucocorticoid as a second treatment modality and administering one or more other chemotherapeutic agents as further treatment modalities, wherein the administration of said isocoumarin derivative when combined with the administration said glucocorticoid and administration of said one or more other chemotherapeutic agents is effective to treat said multiple myeloma.

15 (previously presented): The method of claim 14, wherein said glucocorticoid is dexamethasone.

16 (previously presented): The method of claim 15, wherein said administration of one or more other chemotherapeutic agents is the

administration of vincristine as a third treatment modality and the administration of doxorubicin as a fourth treatment modality.

17 (previously presented): The method of claim 14, wherein said one or more other chemotherapeutic agents is or are selected from the group consisting of vincristine, doxorubicin, cyclophosphamide, etoposide, cisplatin, melphalan, BCNU and idarubicin.

18 (previously presented): The method of claim 14, wherein said glucocorticoid is prednisone.

19 (previously presented): The method of claim 18, wherein said administration of one or more other chemotherapeutic agents is:

- (a) the administration of melphalan as a third treatment modality;
- (b) the administration of cyclophosphamide as a third treatment modality; or
- (c) the administration of vincristine as a third treatment modality, BCNU as a fourth treatment modality, melphalan as a fifth treatment modality and cyclophosphamide as a sixth treatment modality.

20 (previously presented): The method of claim 18, wherein said one or more chemotherapeutic agents is or are selected from the group consisting of melphalan, mitoxantrone, cyclophosphamide, vincristine, procarbazine, cytoxan, BCNU and doxorubicin.